Novelion Therapeutics Inc. (OTCMKTS:NVLNF) major shareholder Stonepine Capital, L.P. bought 100,000 shares of the firm’s stock in a transaction on Friday, October 11th. The shares were purchased at an average cost of $0.61 per share, with a total value of $61,000.00. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
OTCMKTS:NVLNF opened at $0.63 on Tuesday. Novelion Therapeutics Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $0.84.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands.
Recommended Story: Trade War
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.